Housam Haddad, MD
Internal Medicine · Liberty, KYNPI 1467422253
Payments from drug & device makers
Across 387 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Bayer$943
- Amgen$607
- Novartis$572
- GSK$514
- AbbVie$415
- plus $2K from 30 others
What the payments were for
- Food & beverage$6,56999%
- Education$941%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 42 | $1,253 |
| Bayer | 56 | $943 |
| Amgen | 35 | $607 |
| Novartis | 44 | $572 |
| GSK | 36 | $514 |
| AbbVie(2 entities) | 34 | $415 |
| Merck | 24 | $378 |
| Boehringer Ingelheim | 26 | $370 |
| Novo Nordisk | 15 | $220 |
| Mannkind Corporation | 8 | $174 |
| Johnson & Johnson | 8 | $169 |
| Astellas Pharma US Inc | 2 | $106 |
| Sanofi-aventis U.S. LLC | 7 | $103 |
| Lilly USA, LLC | 6 | $86 |
| Vanda Pharmaceuticals Inc. | 3 | $77 |
| Kowa Pharmaceuticals America, Inc. | 4 | $69 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $55 |
| Pfizer | 3 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $50 |
| Abbott | 2 | $47 |
| Esperion Therapeutics, Inc. | 3 | $47 |
| Sumitomo Pharma America, Inc. | 3 | $45 |
| E.r. Squibb & Sons, L.L.C. | 3 | $40 |
| Sunovion Pharmaceuticals Inc. | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Mylan Specialty L.p. | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Biogen | 1 | $19 |
| Viatris Specialty LLC | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,663 in reported general payments places this provider in the 90th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 673 | $334,747 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 327 | $209,151 |
| JanuviaSitagliptin Phosphate | 307 | $182,665 |
| JardianceEmpagliflozin | 285 | $165,528 |
| OzempicSemaglutide | 101 | $114,695 |
| XareltoRivaroxaban | 187 | $109,351 |
| FarxigaDapagliflozin Propanediol | 145 | $94,127 |
| TrulicityDulaglutide | 98 | $90,399 |
| KerendiaFinerenone | 113 | $74,941 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 107 | $67,673 |
| Invega SustennaPaliperidone Palmitate | 24 | $66,301 |
| LinzessLinaclotide | 111 | $58,174 |
| MyrbetriqMirabegron | 131 | $54,596 |
| EntrestoSacubitril/Valsartan | 111 | $53,645 |
| VraylarCariprazine Hcl | 34 | $42,156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $51 | $334,747673 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $514 | $249,840426 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat | $370 | $222,916381 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta, Lokelma | $1,253 | $212,463379 claims |
| MerckJanuvia, Lagevrio (Eua) | $378 | $202,526334 claims |
| Johnson & JohnsonXarelto, Invega Sustenna | $169 | $175,652211 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $86 | $115,611122 claims |
| Novo NordiskOzempic | $220 | $114,695101 claims |
| AbbVieLinzess, Vraylar, Namzaric | $415 | $112,259179 claims |
| BayerKerendia | $943 | $74,941113 claims |
| Astellas Pharma US IncMyrbetriq | $106 | $54,596131 claims |
| NovartisEntresto | $572 | $53,645111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Liberty
- Mark AdamsLondon$15.4M
- Matthew WenkerErlanger$12.8M
- Jason ChesneyLouisville$6.3M
- Neil FarrisLexington$3M
- David JohnsonOwensboro$787K
- Hollis ClarkMurray$780K
- Fares KhaterWhitesburg$412K
- Christopher PhillipsPaducah$315K
- Cynthia Bowman-StroudPaducah$234K
- Bernard BuchananOwensboro$224K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.